Ivo Abraham, PhD, RN

Professor of Practice

Ivo Abraham is a professor (part-time) in the Department of Pharmacy Practice. He has also served on the faculty of Case Western Reserve University (Cleveland, Ohio), University of Virginia (Charlottesville, Va.), and (part-time) Katholieke Universiteit Leuven (Leuven, Belgium); and as visiting professor at Universiteit Maastricht (Maastricht, The Netherlands), University of Florida (Gainesville, Fla.), Rijksuniversiteit Groningen (Groningen, The Netherlands), University of Pennsylvania (Philadelphia, Penn.), and Chang Gung University (Kwei-Shan Tao-Yuan, Taiwan).  He has lectured, consulted, and conducted research throughout the Americas, Europe, the Asia-Pacific region, and Africa. Being part-time, he divides his time between the University of Arizona and Matrix45, a biopharmaceutical research and consulting company, where he serves as chief scientist.

For the past decade or so, Dr. Abraham’s research has focused mainly on clinical outcomes and effectiveness research, in particular how variability in (drug-centric) treatment regimens is associated with variability in patient outcomes. However, instead of merely evaluating effectiveness (does the treatment work?), the work of his research group addresses the equally important questions of when does the treatment work (and when not), what influences whether the treatment works, why does the treatment work in some patients but not in others, why does the treatment work with some clinicians but not with others, why is the treatment tolerated by some patients but not by others, and how much of patient outcomes is related to patient vs. clinician or treatment center?  In this process, his group uses a comprehensive framework of treatment patterns and outcomes assessment, vulnerability profiling, hierarchical modeling, (non-)responder analysis, and pharmacovigilance and drawing methodologies and statistical models from other disciplines into biomedical research.  

More recently, frustrated by the abundance of evidence but clinicians’ persistent low adoption of evidence-based guidelines, he and his colleagues started examining how practicing in accordance with evidence-based guidelines is directly associated with patient outcomes.

He has (co-)authored 260+ articles and 60+ chapters, and has (co-)edited 29 books, monographs, and journal issues. Since 1984, his research has been funded by federal funding agencies, foundations, and corporations.   He has served as appointed ad hoc reviewer for the NIH, the NIMH, and the AHRQ. He currently serves as an expert adviser to the Innovative Medicines Initiative, a joint 2 billion euro undertaking of the European Union and the biopharmaceutical industry to stimulate innovation in human therapeutics.

His educational and scientific honors and awards include an Invitational research fellowship from the Japan Society for the Promotion of Science (2007-2008), which he conducted at Hyogo University and Aomori University.

View UA Profile

Education & Post Graduate Training: 

BS, Nursing, Katholieke Hogeschool Leuven (Leuven, Belgium)
MS, Psychiatric-Mental Health Nursing, University of Michigan
PhD, Clinical Research, University of Michigan 

Select Publications


Patanwala AE, Narayan SW, Haas CE, Abraham I, Sanders A, Erstad BL. "Proposed guidance on cost-avoidance studies in pharmacy practice." Am J Health Syst Pharm. 2021;78(17):1559-1567. PMID: 34007979
Almutairi AR, Erstad BL, McBride A, Slack M, Abraham I. "Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare data." Expert Opin Drug Saf. 2021;20(4):489-497. PMID: 33445985
McBride A, AlRawashdh N, Bartels T, Moore L, Persky D, Abraham I. "Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapy." Future Oncol. 2021;17(26):3485-3497. PMID: 34241542
Narayan SW, Abraham I, Erstad BL, Haas CE, Sanders A, Patanwala AE. "Methods used to attribute costs avoided from pharmacist interventions in acute care: A scoping review." Am J Health Syst Pharm. 2021;78(17):1576-1590. PMID: 34003209
Almutairi AR, Slack M, Erstad BL, McBride A, Abraham I. "Association of immune-checkpoint inhibitors and the risk of immune-related colitis among elderly patients with advanced melanoma: real-world evidence from the SEER-Medicare database." Ther Adv Drug Saf. 2021;12:2042098621991279. PMCID: PMC7970695  PMID: 33796257
AlRawashdh N, Sweasy J, Erstad B, McBride A, Persky DO, Abraham I. "Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985-2017)." Ann Hematol. 2021;100(10):2501-2512. PMID: 34279676
Alkhatib N, Sweitzer NK, Lee CS, et al. "Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure." Am J Cardiovasc Drugs. 2021;21(2):205-217. PMID: 32710439
Moore L, Bartels T, Persky DO, Abraham I, Kumar A, McBride A. "Outcomes of primary and secondary prophylaxis of chemotherapy-induced and febrile neutropenia in bendamustine plus rituximab regimens in patients with lymphoma and chronic lymphocytic leukemia: real-world, single-center experience." Support Care Cancer. 2021;29(8):4867-4874. PMID: 33547525
Hamarneh D, Alkhatib N, Denhaerynck K, et al. "Gender-stratified hierarchical modeling of patient and physician determinants of antihypertensive treatment outcomes: pooled analysis of seven prospective real-world studies with 17,044 patients." Curr Med Res Opin. 2021;37(3):367-375. PMID: 33467935
Kim H-J, Abraham I. "Determinants of the Higher Prevalence and Severity of Subjective Cognitive Impairment in Cancer Patients Compared to Healthy Subjects: Fatigue and Stress." Clin Nurs Res. 2021;30(6):809-817. PMID: 32959682